Regeneron Pharmaceuticals is a biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The Company's products include injections to treat macular edema, moderate-to-severe atopic dermatitis, heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, rheumatoid arthritis. Regeneron also offers injections to treat cryopyrin-associated periodic syndromes and metastatic colorectal cancer. In addition, it develops a trap-based clinical product for the treatment of neovascular glaucoma, and antibody-based clinical programs.

Type
Public
HQ
Tarrytown, US
Founded
1988
Size (employees)
6,200 (est)+15%
Regeneron Pharmaceuticals was founded in 1988 and is headquartered in Tarrytown, US
Report incorrect company information

Regeneron Pharmaceuticals Office Locations

Regeneron Pharmaceuticals has offices in Uxbridge, Dublin, Limerick, Tarrytown and in 2 other locations
Tarrytown, US (HQ)
777 Old Saw Mill River Road
Basking Ridge, US
110 Allen Road
Rensselaer, US
81 Columbia Turnpike
Dublin, IE
Harcourt Centre Harcourt Street
Limerick, IE
Raheen Business Park
Uxbridge, GB
Stockley Park, Heathrow 6-9 The Square
Show all (6)
Report incorrect company information

Regeneron Pharmaceuticals Financials and Metrics

Regeneron Pharmaceuticals Financials

Regeneron Pharmaceuticals's revenue was reported to be $4.86 b in FY, 2016 which is a 18.4% increase from the previous period.
USD

Revenue (Q1, 2018)

1.5 b

Gross profit (Q1, 2018)

1.4 b

Gross profit margin (Q1, 2018), %

95.4%

Net income (Q1, 2018)

478 m

EBIT (Q1, 2018)

567.2 m

Market capitalization (25-May-2018)

31.7 b

Closing share price (25-May-2018)

293.7

Cash (31-Mar-2018)

1 b
Regeneron Pharmaceuticals's current market capitalization is $31.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

2.1 b2.8 b4.1 b4.9 b

Revenue growth, %

34%46%18%

Cost of goods sold

118 m129 m241.7 m194.6 m

Gross profit

2 b2.7 b3.9 b4.7 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

597 m625.7 m665.7 m725.8 m869.6 m998.6 m1.1 b1.2 b1.2 b1.2 b1.3 b1.5 b1.5 b1.5 b

Cost of goods sold

28.3 m27.5 m29.9 m33.7 m42.6 m60.9 m67.2 m78.9 m41.2 m29.9 m61.3 m42.1 m46.4 m69.2 m

Gross profit

568.8 m598.3 m635.8 m692.1 m827 m937.8 m1.1 b1.1 b1.2 b1.2 b1.3 b1.4 b1.5 b1.4 b

Gross profit Margin, %

95%96%96%95%95%94%94%93%97%98%95%97%97%95%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

535.6 m648.7 m809.1 m535.2 m

Inventories

70.4 m128.9 m238.6 m399.4 m

Current Assets

1.8 b2.2 b2.9 b3.2 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

263.2 m461.9 m600.1 m646.6 m507.9 m390.6 m654.6 m604.2 m646.5 m920.4 m811.8 m744.3 m792.1 m1 b

Inventories

86.5 m109.9 m120.3 m133.9 m171.3 m190.7 m303.3 m316.1 m345.6 m466.6 m554.3 m641.6 m820.4 m

Current Assets

1.6 b1.9 b1.9 b2.2 b2.3 b2.3 b2.7 b3.1 b3.2 b3.5 b3.7 b3.9 b4.1 b4.5 b

PP&E

1.7 b1.8 b1.9 b2.3 b2.3 b2.4 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

424.4 m348.1 m636.1 m895.5 m

Depreciation and Amortization

41.2 m52.7 m74.9 m104.7 m

Inventories

(48 m)(61 m)(110 m)(149.8 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

141.3 m65.4 m158.2 m237.9 m76 m270.7 m481.1 m165.7 m377.6 m642.4 m248.9 m636.7 m388.3 m478 m

Depreciation and Amortization

11.5 m24.5 m38.6 m16 m31.3 m52 m23 m48 m75.8 m38.1 m73.2 m36.4 m

Inventories

(15.6 m)(37.3 m)(50.9 m)(5.9 m)(49.9 m)(81.5 m)(62.3 m)(72.9 m)(99.7 m)(69.7 m)(151.5 m)641.6 m(88.8 m)

Accounts Payable

818.4 m
USDY, 2018

Financial Leverage

1.4 x
Show all financial metrics
Report incorrect company information